FDA women’s health leader to open Women’s HealthX 2026

Dr. Kaveeta Vasisht, the FDA’s women’s health chief, will deliver the opening keynote at Women’s HealthX 2026 on Dec. 3-4 in Boston. The summit is aiming to spotlight sex-specific evidence, clinical trial design and broader access to women’s health care across payers, providers and biopharma.

Why it matters: - Women’s HealthX 2026 is positioning itself around a major shift in women’s health: more sex-specific evidence, better clinical trial design and earlier intervention. - The event aims to connect payers, providers, employers and drugmakers around infrastructure that can scale women’s health beyond isolated programs. - The summit is set to focus on areas that shape access and outcomes, including maternal care, chronic pelvic conditions, midlife care and outcomes-based reimbursement.

What happened: - Women’s HealthX announced that Dr. Kaveeta Vasisht, MD, PharmD, will deliver the opening keynote at its inaugural summit. - Vasisht is Associate Commissioner for Women’s Health and Director of the Office of Women’s Health at the U.S. Food and Drug Administration. - The summit will take place Dec. 3-4, 2026, at Encore Boston Harbor in Boston. - Women’s HealthX said the full speaker lineup and registration details are available on the event website.

The details: - Vasisht’s keynote will center on sex-specific evidence generation, lifecycle health research and next-generation clinical trial design. - The program includes senior leaders from Elevance Health, Humana, CVS Health and Blue Cross Blue Shield of Tennessee. - Biopharma and life sciences participants include Novartis, Organon and EMD Serono. - Health systems and providers on the program include Mass General Brigham, WellSpan Health and Corewell Health. - Women’s HealthX described the summit as a cross-sector convening focused on moving beyond siloed point solutions. - The event is being framed as part of a broader push for representative clinical trials under federal Diversity Action Plan mandates. - The release points to recent FDA milestones, including accelerated approval of AstraZeneca’s breast cancer therapy camizestrant guided by ctDNA liquid biopsy biomarkers.

Between the lines: - The speaker mix suggests Women’s HealthX is trying to make women’s health a business and care-delivery issue, not just a clinical specialty topic. - The emphasis on regulators, payers and health systems signals a push toward evidence that can influence reimbursement and access, not only research. - The FDA keynote gives the summit policy weight at a time when sex-differentiated data is drawing more attention across drug development.

What's next: - Women’s HealthX is expected to continue rolling out speaker and registration information ahead of the December summit. - The event will likely use the FDA keynote and multi-sector lineup to frame follow-on discussions on trial design, access and reimbursement. - The full agenda and updates are available through the company’s announcement.